Introduction
============

Drug delivery to tumors is exacerbated by the toxicity to normal tissue in conjunction with low absorption at the tumor-site due to low retention of drugs by the tumor cells. The treatment of solid tumors such as pancreatic cancer, cervical cancer, and breast cancer with chemotherapeutic hydrophobic agents like 'curcumin' is limited by the lack of bioavailability and tissue specificity.[@b1-ijn-4-115] Curcumin is a yellow polyphenol extracted from the rhizome of turmeric, which has strong activity as an anti-cancer agent as it inhibits proliferation of various tumor cells.[@b2-ijn-4-115] Previously, curcumin was shown to suppress many tumorogenic pathways, including the Her2/*neu* pathway, in breast cancer cells.[@b2-ijn-4-115],[@b3-ijn-4-115]

In order to enhance the bioavailability of curcumin, several approaches have been taken including the development of curcumin nanoparticles. Recent studies demonstrated various formulations of curcumin nanoparticles using polymeric materials,[@b4-ijn-4-115],[@b5-ijn-4-115] solid lipids,[@b6-ijn-4-115] and liposomes.[@b7-ijn-4-115]--[@b9-ijn-4-115] Although the use of liposomes reduced the toxicity, no tissue specificity is associated with the liposomes. Additionally, none of the above formulations were derived from natural polymers that would eliminate tissue toxicity while simultaneously increasing bioavailability.

Silk microspheres,[@b10-ijn-4-115],[@b11-ijn-4-115] nanolayers,[@b12-ijn-4-115] and coatings on drug-loaded liposomes[@b13-ijn-4-115],[@b14-ijn-4-115] were previously used for the controlled release of various other drugs. Previously, silk fibroin (SF)-coated liposomal emodin was shown to have higher efficacy against breast cancer cells as compared to the uncoated liposomal emodin due to increased retention of emodin in the presence of SF.[@b14-ijn-4-115] Loading the drug into liposomes and then coating them with SF produced particles that were larger in size than 100 nm.[@b13-ijn-4-115]

Therefore, this study was focused on harnessing the properties of the SF polymer as a drug delivery agent in order to increase the retention, efficacy, and bioavailability of curcumin by packaging it as a nanoparticle (\<100 nm). Moreover, SF was blended with chitosan (CS), since this blend was shown to be biocompatible, biodegradable, and supports the *in vivo* regeneration of tissues.[@b15-ijn-4-115] Both SF and CS are derived from natural biopolymers. In this study, we investigated the fabrication and characterization (size, entrapment efficiency, and *in vitro* drug release) of SF- and CS-derived curcumin nanoparticles. Also, the intracellular uptake and efficacy of curcumin nanoparticles on low and high Her2/*neu*-expressing breast cancer cells was analyzed. Although curcumin was shown to suppress many tumorogenic pathways,[@b2-ijn-4-115],[@b3-ijn-4-115] this is the first time that curcumin nanoparticles have shown efficacy towards breast cancer cells.

Materials and methods
=====================

Preparation of silk fibroin and chitosan blends
-----------------------------------------------

Raw silk (Sao Paulo, Brazil) was generously donated by Dr Sam Hudson (North Carolina State University, Raleigh, NC) and high molecular weight chitosan (82.7% deacetylation) was obtained from Sigma-Aldrich (St. Louis, MO). Processing of SF and preparation of SFCS blends has been described previously.[@b16-ijn-4-115] In brief, raw silk was degummed in 0.25% (w/v) sodium carbonate and 0.25% (w/v) sodium dodecylsulfate (Sigma-Aldrich) for one hour at 100 °C and then dissolved in calcium nitrate tetrahydrate and methanol solution (molar ratio of 1:4:2 Ca:H~2~O:MeOH) at 65 °C. Chitosan was dissolved separately in a 2% acetic acid solution at the same concentration as silk fibroin solution and was mixed together to prepare a particular blend. For example, three parts of SF were mixed with one part of CS to prepare 75:25 SFCS. The SFCS solution was then dialyzed against ultrapure water for four days and filtered. The final solution was 10% w/v of SF or SFCS and diluted 100 times to make 0.1% w/v solutions.

Preparation of nanoparticles
----------------------------

Curcumin powder was weighed (1 mg) and suspended in 100 μl of 25:75, 50:50, or 75:25 SFCS and SF only. These nanoparticles were prepared using the capillary microdot technique. The drug suspension was dispensed on glass slides via a microcapillary. The slides were then frozen overnight and lyophilized. Dry dots containing SFCS-coated curcumin nanoparticles were scraped off the slides and collected in a 1.5 ml centrifuge tube. The SFCS coating was crystallized by suspending nanoparticles in 0.5 ml of 50:50 methanol and 1N sodium hydroxide solution (for SF coating, only methanol was used) for 15 minutes.[@b13-ijn-4-115] The suspension was centrifuged at 8,960 g for 10 minutes, and the supernatant was removed. The pellet containing nanoparticles was rinsed with phosphate-buffered saline (PBS) twice to remove any remaining methanol and sodium hydroxide. PBS rinses were performed by adding 0.5 ml of PBS to the nanoparticles and centrifuging at 8,960 g for 10 minutes. After the second rinse, the SFCS-coated curcumin nanoparticles were suspended in PBS for further analysis.

Size measurement using transmission electron microscopy (TEM)
-------------------------------------------------------------

SFCS-coated curcumin samples suspended in PBS were imaged using a JEM 1010 transmission electron microscope (TEM; JEOL USA Inc., Peabody, MA). Samples were placed on formver-coated and carbon-coated copper grids treated with poly-[l]{.smallcaps}-lysine for one hour. The samples were then blotted dry and imaged. The size of the nanoparticles from TEM images was measured using ImageJ software.

Curcumin entrapment efficiency and release
------------------------------------------

After collecting the nanoparticles from glass slides, the methanol/sodium hydroxide rinse and two subsequent PBS rinses (as defined above) were collected to calculate entrapment efficiency. The curcumin that was not entrapped (not coated with SFCS) was completely soluble in organic solvent and, hence, was collected in the methanol rinses. The amount of curcumin in the samples was measured by reading the absorbance at 424 nm using UV spectrophotometer (ThermoSpectronics, Rochester, NY) and calculated from the curcumin standard in ethanol.[@b5-ijn-4-115] Similarly, for drug release, the nanoparticle suspension was centrifuged at 8,960 g for 10 minutes and absorbance was measured in the supernatant. The pellet was again suspended in PBS for the next time point and kept in a 37 °C incubator shaker.

Cell culture
------------

Breast cancer cell lines MCF-7 (Her2−) and MDA-MB-453 (Her2+) were obtained from American Type Culture Collection (ATCC, Manassas, VA). MCF-7 cells were cultured in Dulbecco Modified Eagle's Medium with F-12 (Invitrogen, Grand Island, NY) and MDA-MB-453 cells in Leibovitz's L-15 medium (ATCC). Both culture mediums were supplemented with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic solution (Invitrogen).

Assay for intracellular uptake of curcumin
------------------------------------------

MCF-7 and MDA-MB-453 cells were seeded in 96-well plates (2,000 cells/well) and incubated overnight. SFCS- or SF-coated nanocurcumin was added to each well at a concentration of 83.3 μg curcumin/well and incubated for four days. The nanoparticles contained in the medium were removed from the wells. Cells were lysed in 100 μl of dimethyl sulfoxide (DMSO; Fisher Scientific, Pittsburg, PA). A 50 μl cell lysis suspension was reserved for absorbance measurement and the other 50 μl for fluorescence measurements using a VersaFluor fluorometer (Bio-Rad Laboratories, Hercules, CA). Two filters were utilized with 480 nm excitation and 520 nm emission wavelengths. Since curcumin has auto-fluorescence properties,[@b9-ijn-4-115] fluorescence assays were used in conjunction with absorbance to confirm the curcumin uptake measurements.

Cell viability assay
--------------------

To measure the efficacy of nanocurcumin on MCF-7 and MDA-MB-453, the cells were seeded in 96-well plates (2,000 cells/well) and incubated overnight. Nanocurcumin coated with SFCS or SF was added to each well at a concentration of 83.3 μg curcumin/well and incubated for four days. The nanoparticles contained in the medium were removed from the wells and a CellQuanti-MTT cell viability assay kit (BioAssay Systems, Hayward, CA) was used to determine the viability of cells remaining in each well. Briefly, 80 μl of culture medium and 15 μl of MTT reagent were added to each well and incubated for four hours. Then, MTT solubilization solution (100 μl) was added to each well, and the plates were placed on a shaker for one hour. The absorbance readings were taken at 570 nm using a MRX Microplate Reader (Dynex Technologies, Guernsey, Channel Islands, UK).

Statistical analysis
--------------------

All data analysis was performed using SigmaStat statistical program. One-way analysis of variance (ANOVA) was used with post-hoc Tukey test for pair-wise comparisons. All data was represented as mean ± standard error of mean (SEM) and level of significance was chosen as p \< 0.05.

Results
=======

Nanoparticle size measurement
-----------------------------

SF- or SFCS-encapsulated curcumin nanoparticles fabricated with either 0.1% w/v or 10% w/v SF or SFCS were imaged using TEM to characterize the size ([Figure 1](#f1-ijn-4-115){ref-type="fig"}). Size measurements of curcumin encapsulated particles showed that all formulations resulted in particles of sizes less than 100 nm except for 0.1% w/v 50:50 SFCS (130 ± 4.2 nm) ([Figure 2](#f2-ijn-4-115){ref-type="fig"}). Particle size of curcumin coated with 0.1% w/v SF was significantly lower than 0.1% w/v 50:50 SFCS (p \< 0.001) and higher than 0.1% w/v 25:75 SFCS and 0.1% w/v 75:25 SFCS (p \< 0.001) fabricated particles. The particle size for 10% w/v 75:25 SFCS was significantly higher than 10% w/v SF, 10% w/v 25:75 SFCS, and 10% w/v 50:50 SFCS (p \< 0.001).

Although there are differences in the size of the nanoparticles between high and low concentrations of SF content, no specific trend was noted. The size of particles coated with 0.1% w/v SF and 0.1% w/v 50:50 SFCS was significantly higher than 10% w/v SF and 10% w/v 50:50 SFCS (p \< 0.001). However, 0.1% w/v 25:75 SFCS-coated nanoparticles were smaller than 10% w/v 25:75 SFCS-coated particles (p \< 0.05). The size of SF and SFCS control particles (without drug) were also measured (data not shown) and found to be comparable with curcumin-loaded particles.

Curcumin entrapment efficiency
------------------------------

The entrapment of curcumin was more than 96% for SF-coated nanoparticles for both 0.1% and 10% SF. The entrapment efficacy decreased to 64%--73% for SFCS coated nanoparticles regardless of concentration of SF and CS ([Figure 3](#f3-ijn-4-115){ref-type="fig"}). Curcumin entrapment was significantly higher for 0.1% w/v SF (p \< 0.01) and 10% w/v SF (p \< 0.05) compared to all SFCS blends.

*In vitro* curcumin release from nanoparticles
----------------------------------------------

The curcumin release profiles for both 0.1% w/v and 10% w/v preparations showed an initial burst release (up to two days) of curcumin from both SF and SFCS blends ([Figure 4](#f4-ijn-4-115){ref-type="fig"}). However, curcumin release from SFCS blends did not increase any further over eight days. The high and low concentrations of SF-coated curcumin nanoparticles consistently released curcumin in large amounts over eight days. As shown in [Figure 4](#f4-ijn-4-115){ref-type="fig"}, cumulative release of curcumin from SF-coated nanoparticles at day 8 was significantly higher than all other SFCS-blend nanoparticles (p \< 0.05 for 0.1% w/v and p \< 0.001 for 10% w/v solutions). Also, at day 8 the release from 10% SF was significantly greater than 0.1% w/v SF (p \< 0.001).

The release of drugs from polymers has been previously modeled by the power law equation.[@b17-ijn-4-115]
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The ratio of *M~t~* and *M*~∞~, the amounts of drug at any time *t* and at infinite time, respectively, was plotted against time, *t*, resulting in the derivation of parameters *k* and *n*, which are dependent upon the composition/structure of the coating and release mechanism, respectively. [Table 1](#t1-ijn-4-115){ref-type="table"} shows the values of *n* and *k* for all the nanoparticle formulations. The parameter *n* ranged from 0.15 to 0.55 for the various nanoparticle formulations in [Table 1](#t1-ijn-4-115){ref-type="table"}, suggesting a diffusion-based release mechanism of curcumin from the nanoparticles.[@b17-ijn-4-115] Based on *k* values, the amount of drug released was significantly higher for 10% w/v SF as compared to 0.1% w/v SF and all other SFCS blends (p \< 0.001).

Intracellular uptake of curcumin
--------------------------------

The absorbance measurements of intracellular uptake of curcumin by Her2/*neu* low- and high-expressing breast cancer cells show that the curcumin uptake was highest from SF-coated nanoparticles as compared to the respective 0.1% w/v and 10% w/v SFCS blend groups ([Figure 5](#f5-ijn-4-115){ref-type="fig"}). These differences were similar for both MCF-7 and MDA-MB-453 cells. The fluorescence measurements also showed similar uptake data as compared to the absorbance measurements ([Figure 6](#f6-ijn-4-115){ref-type="fig"}). Interestingly, curcumin uptake by MDA-MB-453 cells was higher from 10% w/v SF-coated nanoparticles than 0.1% w/v SF-coated nanoparticles as measured by both absorbance and fluorescence.

Curcumin nanoparticle efficacy against breast cancer cells
----------------------------------------------------------

The efficacy of curcumin nanoparticle formulations was measured for both MCF-7 and MDA-MB-453 cells using the MTT assay ([Figure 7](#f7-ijn-4-115){ref-type="fig"}). The number of cells in the control samples (no nanoparticles) increased from 2,000 (initial density) to 3,563 ± 215 (MCF-7) and 3,267 ± 864 (MDA-MB-453) over a period of four days. Exposure of 0.1% w/v SF and 10% w/v SF nanocurcumin to MCF-7 and MDA-MB-453 cells significantly decreased the number of viable cells compared to controls (p \< 0.01). On the other hand, there was no difference in cell viability for the SFCS blends as compared to the control group. Also, the efficacy of 0.1% w/v SF was higher than 0.1% w/v 25:75 SFCS for MCF-7 cells (p \< 0.01) and 0.1% w/v 50:50 SFCS for MDA-MB-453 cells (p \< 0.01). Similarly, 10% w/v SF nanocurcumin had significantly higher efficacy against both types of breast cancer cells as compared to 10% w/v 25:75 SFCS and 10% w/v 50:50 SFCS (p \< 0.05).

Discussion
==========

SF- and SFCS-coated curcumin nanoparticles (\<100 nm) were fabricated and characterized. SF-coated nanoparticles showed the highest entrapment and release of curcumin, which resulted in higher intracellular uptake and efficacy towards breast cancer cells. To our knowledge, only two other studies reported the fabrication of curcumin nanoparticles of less than 100 nm,[@b4-ijn-4-115],[@b5-ijn-4-115] however neither was manufactured from biologically derived regenerative biomaterials such as SF and CS.[@b15-ijn-4-115]

Curcumin entrapment was higher in SF-coated nanopar-ticles compared to all other SFCS blend formulations. The introduction of CS in the nanoparticle formulation of SF resulted in an increase of its hydrophilic character since CS is a water-carrying glucosamine molecule. Curcumin is a hydrophobic drug and hence the presence of CS with SF may have resulted in reducing the entrapment efficiency of curcumin. A very small amount (0.09--0.13 μg) of curcumin was released from the SFCS-coated nanoparticles as compared to SF-coated nanoparticles (0.32--0.68 μg) over eight days, which may have resulted from lower initial entrapment. The curcumin entrapment was initially low in SFCS coated nanoparticles resulting in the overall reduced release. Due to lower entrapment, the diffusion gradient of curcumin release from SFCS nanoparticles was also less as compared to SF-encapsulated curcumin nanoparticles. Previously, drug release from SF-coated liposomes was also found to be diffusion-controlled.[@b13-ijn-4-115]

The intracellular uptake of curcumin was also highest for the SF-coated nanoparticles compared to SFCS blends, which followed the curcumin entrapment and release data. Other than the nanoparticle size, the effect of concentration (10% w/v vs 0.1% w/v) was only evident in the intracellular uptake of curcumin by MDA-MD-453 cells. The curcumin uptake was significantly higher from 10% w/v SF than 0.1% w/v SF nanoparticles as measured by both absorbance and fluorescence assays. The effect of SF on the efficacy of breast cancer cells was previously studied with the SF coating of emodin-loaded liposomes. The SF coating of emodin-loaded liposomes was shown to have higher efficacy in Her2/*neu* high-expressing breast cancer cells (MDA-MB-453).[@b14-ijn-4-115] Due to higher retention of emodin in the Her2/*neu* high expressing breast cancer cells, more signal transduction pathways were affected resulting in higher efficacy as compared to uncoated emodin-loaded liposomes. In this study, the higher SF content (10% w/v) resulted in higher uptake and intracellular residence time for curcumin, which also increased efficacy against breast cancer cells. While the SF coating of emodin in the study by Cheema and colleagues was 0.1% w/v SF,[@b14-ijn-4-115] we found that increasing the SF coating amount from 0.1% w/v to 10% w/v increased the curcumin entrapment and cellular uptake significantly, thereby affecting efficacy.

The efficacy of SF-coated nanocurcumin on breast cancer cells was significantly higher than SFCS-coated nanocurcumin. Efficacy data followed the curcumin uptake data, which showed high uptake of curcumin from SF-coated nanoparticles and hence reduced viability of Her2/*neu* high-expressing breast cancer cells. Previously, curcumin was shown to suppress Her2 and nuclear factor-κβ pathways in breast cancer cells.[@b3-ijn-4-115],[@b18-ijn-4-115] Interestingly, Her2/*neu* low-expressing MCF-7 breast cancer cells also undergo apoptosis upon exposure to curcumin nanoparticles. Since curcumin is known to act through many pathways in various cancer cells,[@b2-ijn-4-115] there may be a down modulation of more than one pathway in breast cancer cells due to longer availability of curcumin via SF nanoparticles.[@b14-ijn-4-115]

One of the limitations of this study was the minor drug loss during the transfer of nanoparticles from the glass slides. Although the use of the same procedure to transfer the nanoparticles should have minimized this effect when comparing groups. It was difficult to calculate the amounts of drug loss because entrapment efficiencies were calculated based on the un-entrapped drug during methanol/sodium hydroxide wash and the initial amount of drug used to mix with the SF or SFCS blends. However, it was evident from intracellular uptake and efficacy data that SF-coated nanoparticles entrapped and re7leased the most drug as compared to other SFCS blend-coated nanoparticles. When considering the hydrophobic nature of curcumin with respect to the hydrophilic nature of chitosan, as mentioned earlier, this conclusion is logical. Another limitation of the study was the release of very small amounts of curcumin over time, which may be related to the medium (PBS) into which the release study was conducted. It is possible that the amount of released curcumin would be affected under serum or plasma conditions.

The treatment of several cancers in the future will be influenced by the ability of scientists to produce drug formulations that have high drug availability at tumor sites, sustained and long-term release, and minimal to no toxicity to healthy tissues. Biologically derived nanoparticles offer great promise in this regard due to the minimization of adverse effects while increasing the efficacy of the entrapped drug.

In conclusion, the SF- and SFCS-coated curcumin nanoparticles were fabricated using a novel technique. The size of the nanoparticles that showed high curcumin entrapment and efficacy towards breast cancer cells was less than 100 nm. Nanoparticles of curcumin encapsulated with pure SF showed the highest curcumin entrapment, release, intra-cellular uptake, and efficacy towards breast cancer cells as compared to SFCS curcumin nanoparticles. The coating of SF can be used for nanoparticle preparation of numerous drugs or therapeutics for localized and long-term release for the treatment of cancer and many other diseases.
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![TEM images of the curcumin nanoparticle formulations. All blends of SFCS and SF alone were made of 10% w/v solution in these TEM images.\
**Abbreviations:** SF, silk fibroin; SFCS, silk fibroin and chitosan; TEM, transmission electron microscopy.](ijn-4-115f1){#f1-ijn-4-115}

![Curcumin nanoparticle sizes as measured from TEM images. Between 22 to 50 nanoparticles were measured from TEM images for each formulation. \*p \< 0.001 vs 0.1% SF, ^†^p \< 0.001 vs 0.1% 25:75 SFCS, ^φ^p \< 0.05 vs 10% 25:75 SFCS, ^‡^p \< 0.001 vs 0.1% 50:50 SFCS, ^\#^p \< 0.001 vs 10% 75:25 SFCS.\
**Abbreviations:** SF, silk fibroin; SFCS, silk fibroin and chitosan; TEM, transmission electron microscopy.](ijn-4-115f2){#f2-ijn-4-115}

![Curcumin entrapment within nanoparticles (n = 3). \*p \< 0.01 vs 0.1% SF, ^†^p \< 0.001 vs 0.1% SF, ^‡^p \< 0.05 vs 10% SF, ^φ^p \< 0.01 vs 10% SF.\
**Abbreviations:** SF, silk fibroin.](ijn-4-115f3){#f3-ijn-4-115}

![Cumulative curcumin release from nanoparticles over the period of eight days (n = 3). All blends of SFCS and SF alone were made of (**a**) 0.1% solution and (**b**) 10% solution.\
**Abbreviations:**SF, silk fibroin; SFCS, silk fibroin and chitosan.](ijn-4-115f4){#f4-ijn-4-115}

![Intracellular uptake of curcumin by breast cancer cells as measured by absorbance assay after exposure to curcumin nanoparticles for four days (n = 3). (**a**) MCF-7, \*p \< 0.01 vs 0.1% SF, ^†^p \< 0.001 vs 10% SF (**b**) MDA-MB-453, ^‡^p \< 0.001 vs 0.1% SF, ^φ^p \< 0.001 vs 10% SF, ^\#^p \< 0.01 vs 10% SF.\
**Abbreviation:** SF, silk fibroin.](ijn-4-115f5){#f5-ijn-4-115}

![Intracellular uptake of curcumin by breast cancer cells as measured by fluorescence assay after exposure to curcumin nanoparticles for four days (n = 3). (**a**) MCF-7, \*p \< 0.01 vs 0.1% SF, ^†^p \< 0.05 vs 10% SF (**b**) MDA-MB-453, ^‡^p \< 0.001 vs 0.1% SF, ^φ^p \< 0.001 vs 10% SF.\
**Abbreviation:** SF, silk fibroin.](ijn-4-115f6){#f6-ijn-4-115}

![Cell viability measured by MTT assay after exposure to curcumin nanoparticles for four days (n = 3). (**a**) MCF-7, \*p \< 0.001 vs control, ^†^p \< 0.01 vs 0.1% 25:75 SFCS, ^‡^p \< 0.05 vs 10% 25:75 SFCS and 10% 50:50 SFCS (**b**) MDA-MB-453, \*p \< 0.01 vs control, ^†^p \< 0.01 vs 0.1% 50:50 SFCS, ^‡^p \< 0.05 vs 10% 25:75 SFCS and 10% 50:50 SFCS.\
**Abbreviations:** SF, silk fibroin; SFCS, silk fibroin and chitosan.](ijn-4-115f7){#f7-ijn-4-115}

###### 

The exponent 'n' and constant 'k' values from the power law equation for various nanoparticle formulations.

  **Coatings**      **n**         **k (**×**10**^−4^**per/day)**
  ----------------- ------------- --------------------------------
  0.1% SF           0.55 ± 0.10   0.9 ± 0.1
  0.1% 25:75 SFCS   0.25 ± 0.05   1.0 ± 0.4
  0.1% 50:50 SFCS   0.17 ± 0.05   1.0 ± 0.5
  0.1% 75:25 SFCS   0.15 ± 0.05   0.8 ± 0.1
  10% SF            0.32 ± 0.03   3.0 ± 0.0
  10% 25:75 SFCS    0.28 ± 0.18   0.5 ± 0.07
  10% 50:50 SFCS    0.48 ± 0.17   0.6 ± 0.06
  10% 75:25 SFCS    0.45 ± 0.08   0.6 ± 0.2

**Abbreviations:** SF, silk fibroin; SFCS, silk fibroin and chitosan.
